Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Tivantinib
Synonyms
Therapy Description

Tivantinib (ARQ197) is a selective MET inhibitor, which may induce cell death in tumor cells overexpressing MET, although the antimitotic effect may be more responsible for the anti-tumor activity (PMID: 28246274).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Tivantinib ARQ197|ARQ 197|ARQ-197 MET Inhibitor 51 Tivantinib (ARQ197) is a selective MET inhibitor, which may induce cell death in tumor cells overexpressing MET, although the antimitotic effect may be more responsible for the anti-tumor activity (PMID: 28246274, PMID: 32569187, PMID: 32073648).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown multiple myeloma no benefit Tivantinib Phase II Actionable In a Phase II trial, Tivantinib (ARQ197) treatment only resulted in stable disease in 36% (4/11) of patients with relapsed or refractory multiple myeloma (PMID: 28337527). 28337527
Unknown unknown alveolar soft part sarcoma not applicable Tivantinib Phase II Actionable In a Phase II trial, tivantinib resulted in modest activity, in which 27 patients with alveolar soft part sarcoma had a median PFS of 5.5 months (PMID: 22605650). 22605650
Unknown unknown stomach carcinoma not applicable Tivantinib Phase II Actionable In a Phase II trial, Tivantinib (ARQ197) demonstrated efficacy in previously treated patients with metastatic gastric cancer (PMID: 24337769). 24337769
Unknown unknown renal cell carcinoma not applicable Tivantinib Phase II Actionable In a Phase II trial, tivantinib resulted in modest activity in which six patients with renal cell carcinoma had a median PFS of 1.9 months (PMID: 22605650). 22605650
Unknown unknown Advanced Solid Tumor not applicable Tivantinib Phase I Actionable In a Phase I trial, Tivantinib (ARQ 197) demonstrated safety and some anti-tumor activity in patients with advanced solid tumors (PMID: 21976535). 21976535
Unknown unknown clear cell sarcoma not applicable Tivantinib Phase II Actionable In a Phase II trial, tivantinib resulted in modest activity, in which 11 patients with clear cell sarcoma had a median PFS of 1.9 months (PMID: 22605650). 22605650

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status
NCT02150733 Phase I Tivantinib Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment Completed
NCT01755767 Phase III Tivantinib Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma Who Have Been Treated With One Prior Therapy Completed
NCT01468922 Phase I Tivantinib Pazopanib Pazopanib and ARQ 197 for Advanced Solid Tumors Completed


Additional content available in CKB BOOST